专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20060223846A1 Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists 审中-公开
标题翻译：氮杂桥连双环氨基酸衍生物作为α4整联蛋白拮抗剂
公开(公告)号：US20060223846A1
公开(公告)日：2006-10-05
申请号：US11370665
申请日：2006-03-08
申请人： Alexey Dyatkin , Yong Gong , Wei He , Tamara Miskowski
发明人： Alexey Dyatkin , Yong Gong , Wei He , Tamara Miskowski
IPC分类号： C07D453/02 , A61K31/46
CPC分类号： C07D453/02 , C07D453/06
摘要： The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful α4 integrin receptor antagonists and, in particular, α4β1 and α4β7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.
摘要翻译：本发明涉及具有式（I）的氮杂桥联双环化合物及其药学上可接受的盐。该化合物是有用的α4整联蛋白受体拮抗剂，特别是α4β1和α4β7整联蛋白受体拮抗剂。本发明进一步涉及本发明化合物用于治疗整联蛋白介导的病症的方法，包括但不限于炎症性疾病，自身免疫性疾病和细胞增殖性疾病，制备化合物的方法和制备中间体，衍生物和其药物组合物。

42. 发明授权

US06960597B2 Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists 失效
标题翻译：氮杂桥连双环氨基酸衍生物作为α4整联蛋白拮抗剂
公开(公告)号：US06960597B2
公开(公告)日：2005-11-01
申请号：US09891602
申请日：2001-06-26
申请人： Alexey B. Dyatkin , Bruce E. Maryanoff , William J. Hoekstra , Wei He , William A. Kinney
发明人： Alexey B. Dyatkin , Bruce E. Maryanoff , William J. Hoekstra , Wei He , William A. Kinney
IPC分类号： A61K38/00 , A61P1/04 , A61P9/10 , A61P11/06 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07D209/52 , C07D453/06 , C07K5/06 , A61K31/46 , C07D221/22 , C07D401/12
CPC分类号： C07D453/06 , C07D209/52
摘要： The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful (α4 integrin receptor antagonists and, in particular, α4β1 and α4β7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.
摘要翻译：本发明涉及具有式（I）的氮杂桥联双环化合物及其药学上可接受的盐。该化合物是有用的（α4整联蛋白受体拮抗剂，特别是α4β1和α4β7整联蛋白受体拮抗剂。本发明还涉及本发明化合物用于治疗整联蛋白介导的病症的方法，包括但不限于炎症性疾病，自身免疫性疾病和细胞增殖性疾病，制备化合物的方法和制备中间体的方法，其衍生物和药物组合物。

43. 发明申请

US20050192279A1 Pyridazinones as antagonists of alpha4 integrins 审中-公开
标题翻译：哒嗪酮作为α4整联蛋白的拮抗剂
公开(公告)号：US20050192279A1
公开(公告)日：2005-09-01
申请号：US11054190
申请日：2005-02-09
申请人： Kent Barbay , Alexey Dyatkin , Yong Gong , Wei He , Tamara Miskowski
发明人： Kent Barbay , Alexey Dyatkin , Yong Gong , Wei He , Tamara Miskowski
IPC分类号： A61K31/50 , A61K31/501 , C07D237/14 , C07D237/16 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/12 , C07D453/06 , C07D491/04 , C07D498/04 , C07D43/02
CPC分类号： C07D237/14 , C07D237/16 , C07D403/10 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/10 , C07D453/06 , C07D491/04
摘要： The present invention relates to certain novel compounds of Formula (I): methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders.
摘要翻译：本发明涉及某些式（I）的新化合物：制备这些化合物，组合物，中间体及其衍生物的方法和用于治疗整联蛋白介导的病症。

44. 发明申请

US20050176755A1 Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists 审中-公开
标题翻译：氮杂桥连双环氨基酸衍生物作为α4整联蛋白拮抗剂
公开(公告)号：US20050176755A1
公开(公告)日：2005-08-11
申请号：US10976091
申请日：2004-10-27
申请人： Alexey Dyatkin , Yong Gong , Tamara Miskowski , Wei He
发明人： Alexey Dyatkin , Yong Gong , Tamara Miskowski , Wei He
IPC分类号： C07D451/14 , C07D453/06 , C07D453/04 , A61K31/407 , A61K31/46
CPC分类号： C07D453/06
摘要： The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful α4 integrin receptor antagonists and, in particular, α4β1 and α4β7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.
摘要翻译：本发明涉及具有式（I）的氮杂桥联双环化合物及其药学上可接受的盐。该化合物是有用的α4整联蛋白受体拮抗剂，特别是α4β1和α4β7整联蛋白受体拮抗剂。本发明进一步涉及本发明化合物用于治疗整联蛋白介导的病症的方法，包括但不限于炎症性疾病，自身免疫性疾病和细胞增殖性疾病，制备化合物的方法和制备中间体，衍生物和其药物组合物。

45. 发明申请

US20050172349A1 Genetic modification of C57 mice 失效
标题翻译： C57小鼠的遗传修饰
公开(公告)号：US20050172349A1
公开(公告)日：2005-08-04
申请号：US10768350
申请日：2004-01-30
申请人： Wei He , Wei Weng
发明人： Wei He , Wei Weng
IPC分类号： A01K67/00 , A01K67/027 , C12N5/00 , C12N5/02 , C12N15/00 , C12N15/873 , C12N5/06
CPC分类号： A01K67/0275 , A01K2227/105 , C12N15/873 , C12N2517/10
摘要： The present invention relates generally to the field of generating genetically modified C57 mice. More particularly, the present invention pertains to 1) blastocyst-derived mouse embryonic stem cell (ES) cell lines including, but not limited to, the IC1, IC2, IAC1, IAC2, IAC3, IAC4, IAC5, IAC6, IAC7 or IAC8 ES cell line, 2) to efficient methods of making genetically modified C57 mice by introducing the modified C57 ES cells into the mouse blastocysts of either the same mouse strain and/or color of albino C57 strain, or other C57 strain, to generate genetically modified novel, useful and hereto unknown models of C57 mice, and to methods for identifying the chimerism of chimeras which can be not known by coat color.
摘要翻译：本发明一般涉及生产转基因C57小鼠的领域。更具体地说，本发明涉及1）囊胚来源的小鼠胚胎干细胞（ES）细胞系，包括但不限于IC1，IC2，IAC1，IAC2，IAC3，IAC4，IAC5，IAC6，IAC7或IAC8 ES 细胞系，2）通过将修饰的C57ES细胞引入与白化C57株或其他C57菌株相同的小鼠品系和/或颜色的小鼠胚泡中来生产经遗传修饰的C57小鼠的有效方法，以产生转基因小鼠，有用的和未知的C57小鼠模型，以及用于鉴定嵌合体的嵌合体的方法，其可以不被外壳颜色所知。

46. 发明授权

US06859151B2 Digital data transforming method 失效
标题翻译：数字数据转换方法
公开(公告)号：US06859151B2
公开(公告)日：2005-02-22
申请号：US10240707
申请日：2001-04-26
申请人： Dake He , Wei He
发明人： Dake He , Wei He
IPC分类号： G06F17/22 , H03M7/04 , H03M7/30 , H03M7/00
CPC分类号： H03M7/04 , G06F17/2217
摘要： A coding transformation method includes the steps of dividing an input data into blocks with the length of 13 bits, where the original data set X includes all 8192 13-bit symbols and 12 filling-bit symbols, and uses 91 printable characters in the output representation of the input data. The output set Y is a sub-set of the direct product R91×R91, with R91 being a set of 91 printable ASCII characters. The reversible coding mapping relationship is Base91[x]=(ch1, ch2)=(R91—CH[x/91], R91—CH[x%91]) where xεX, ch1, ch2εR91. For an input data block less than 13-bits long, n bits are added to the specified side to make it become a complete block with the image of the block of data in the direct product R91×R91.
摘要翻译：编码变换方法包括以下步骤：将输入数据划分成长度为13位的块，其中原始数据集X包括所有8192个13位符号和12个填充位符号，并且在输出表示中使用91个可打印字符的输入数据。输出集Y是直接产品R91xR91的子集，其中R91是91个可打印的ASCII字符的集合。可逆编码映射关系在其中xepsilon，ch1，ch2epsilonR91。对于小于13位长的输入数据块，在指定端添加n位，使其成为直接产品R91xR91中数据块的图像的完整块。

47. 发明授权

US06696434B2 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases 失效
标题翻译：抑制血小板衍生生长因子和/或p56lck酪氨酸激酶的喹啉和喹喔啉化合物
公开(公告)号：US06696434B2
公开(公告)日：2004-02-24
申请号：US10317464
申请日：2002-12-12
申请人： Michael R. Myers , Wei He , Alfred P. Spada , Martin P. Maguire
发明人： Michael R. Myers , Wei He , Alfred P. Spada , Martin P. Maguire
IPC分类号： A61K3133
CPC分类号： C07D215/38 , C07D215/20 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D453/06
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
摘要翻译：本发明涉及抑制血小板衍生生长因子或p56酪氨酸激酶活性的喹啉/喹喔啉化合物，包含这些化合物的药物组合物，以及这些化合物用于治疗患有或患有疾病/ 涉及细胞分化，增殖，细胞外基质产生或介体释放和/或T细胞活化和增殖的条件。

48. 发明授权

US06482834B2 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases 失效
标题翻译：抑制血小板衍生生长因子和/或p56lck酪氨酸激酶的喹啉和喹喔啉化合物
公开(公告)号：US06482834B2
公开(公告)日：2002-11-19
申请号：US09828633
申请日：2001-04-06
申请人： Alfred P. Spada , Wei He , Michael R. Myers
发明人： Alfred P. Spada , Wei He , Michael R. Myers
IPC分类号： A61K3147
CPC分类号： C07D215/20 , C07D215/38 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D453/06
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
摘要翻译：本发明涉及抑制血小板衍生生长因子或p56lck酪氨酸激酶活性的喹啉/喹喔啉化合物，包含这些化合物的药物组合物，以及这些化合物用于治疗患有或受到涉及细胞的病症/病症的患者的用途分化，增殖，细胞外基质产生或介质释放和/或T细胞活化和增殖。

49. 发明授权

US09822309B2 High carbon concentration biomass and biosolids slurry preparation using a hydro-thermal pretreatment 有权
公开(公告)号：US09822309B2
公开(公告)日：2017-11-21
申请号：US13038134
申请日：2011-03-01
申请人： Chan Seung Park , Joseph Norbeck , Wei He
发明人： Chan Seung Park , Joseph Norbeck , Wei He
IPC分类号： C10B53/02 , C10J3/00 , C10L5/44 , C10L9/00 , C10L1/32 , C10L9/08
CPC分类号： C10B53/02 , C10J3/00 , C10J2300/0903 , C10J2300/0916 , C10J2300/093 , C10J2300/0973 , C10L1/326 , C10L5/44 , C10L9/00 , C10L9/086 , Y02E50/10 , Y02E50/14 , Y02E50/30
摘要： Provided is a process where the biomass and bisolids are hydrothermally treated under a reductive gas. Using this process a high carbon content pumpable mixture of biomass and biosolid slurry is produced with a viscosity value of less than 1.5.

50. 发明授权

US09613779B2 Scanning transmission electron microscope with variable axis objective lens and detective system 有权
公开(公告)号：US09613779B2
公开(公告)日：2017-04-04
申请号：US14940102
申请日：2015-11-12
申请人： Shuai Li , Wei He , Zhongwei Chen
发明人： Shuai Li , Wei He , Zhongwei Chen
IPC分类号： H01J37/21 , H01J37/145 , H01J37/147 , H01J37/28
CPC分类号： H01J37/145 , H01J37/1477 , H01J37/21 , H01J37/28 , H01J2237/0473 , H01J2237/2802
摘要： The present invention provides a scanning transmission electron microscope (STEM). In the STEM, a specimen is sandwiched between a variable axis objective lens and a variable axis collection lens. The axis of the collection lens varies along with the variation of the objective lens axis in a coordinated manner. The STEM of the invention exhibits technical merits such as large scanning field, high image resolution across the entire scanning field, and high throughput, among others.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式